Policy dividends continue to be released, and the pharmaceutical retail industry welcomes new opportunities for transformation

Recently, the policy dividends in the pharmaceutical retail industry have been continuously released, and the pace of transformation and integration upgrades is accelerating. The Ministry of Commerce and eight other departments recently jointly issued the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry," introducing a series of support measures focusing on industry integration, prescription outflow, commercial insurance, and more, to promote the transformation and upgrading of the pharmaceutical retail industry. Industry insiders indicate that with the simultaneous advancement of policy guidance, market clearing, and model innovation, China's pharmaceutical retail industry is entering a new stage of structural optimization, increased concentration, and reconstruction of profit models, where leading enterprises with scale advantages and integration capabilities will significantly benefit. (China Securities Journal)